Matches in SemOpenAlex for { <https://semopenalex.org/work/W2924562010> ?p ?o ?g. }
- W2924562010 abstract "Oral mucositis (OM) is one of the main side effects of the head and neck cancer treatment, particularly radiotherapy and/or chemotherapy. OM is characterised by ulcers, erythema, dysphagia, xerostomia and increased susceptibility to opportunistic infections. In the perspective of finding pharmacological therapies to prevent inflammation and ulceration of OM, the investigation of the pleiotropic effect of commercial drugs is needed, among them gliclazide, an antidiabetic drug. This study aimed to evaluate the effect of gliclazide in an experimental OM model induced by 5-fluorouracil. Male hamsters were pre-treated with oral gliclazide (1, 5, or 10 mg/kg) for ten days. Cheek pouch samples were subjected to histopathological and immunohistochemical analysis (COX2, iNOS, MMP-2, NFκB P65, GPx) and imunofluorescence (P-selectin). IL-1β and TNF-α levels, Myeloperoxidase activity (MPO) and malondialdehyde (MDA) levels were investigated by ultraviolet-visible spectroscopy analysis. NFκB NLS P50 protein levels were analysed by western blotting. The group treated with gliclazide at a dose of 10mg/kg showed presence of erythema, no evidence of erosion, and absence of mucosal ulceration with a score of 1 (1-2) (p<0.01). Histopathological data for the group treated with gliclazide 10mg/kg showed re-epithelialization, discrete mononuclear inflammatory infiltrate and absence of hemorrhage, edema, ulcers and abscesses with a score of 1 (1-1), (p<0.01). Treatment with gliclazide 10 mg/kg reduced MPO activity (p<0.001), MDA levels (p<0.001) and NFκB NLS P50 (p<0.05) protein levels, resulting in low immunostaining to Cox-2, iNOS (p<0.05), NFκB P65 (p<0.05), and negative immunoreaction to MMP-2 (p<0.001). However, it appeared that for Gpx1, the staining was restored in the GLI 10-FUT group compared with 5FUT/saline (p <0.05). Immunofluorescence revealed decreased levels of P-selectin (p<0.001) after treatment with gliclazide 10mg/kg (p<0.05). In summary, gliclazide accelerated mucosal recovery and reduced oxidative stress and inflammation in the 5-FU-induced OM in hamsters." @default.
- W2924562010 created "2019-04-01" @default.
- W2924562010 creator A5034704040 @default.
- W2924562010 creator A5035556877 @default.
- W2924562010 creator A5042133263 @default.
- W2924562010 creator A5042851658 @default.
- W2924562010 creator A5045804141 @default.
- W2924562010 creator A5048902087 @default.
- W2924562010 creator A5058865296 @default.
- W2924562010 creator A5077508602 @default.
- W2924562010 creator A5081444992 @default.
- W2924562010 creator A5086070985 @default.
- W2924562010 date "2019-03-26" @default.
- W2924562010 modified "2023-10-03" @default.
- W2924562010 title "Gliclazide Prevents 5-FU-Induced Oral Mucositis by Reducing Oxidative Stress, Inflammation, and P-Selectin Adhesion Molecules" @default.
- W2924562010 cites W1511449329 @default.
- W2924562010 cites W1531159623 @default.
- W2924562010 cites W1603054792 @default.
- W2924562010 cites W1606925436 @default.
- W2924562010 cites W1626249149 @default.
- W2924562010 cites W1965105866 @default.
- W2924562010 cites W1978454448 @default.
- W2924562010 cites W1983034942 @default.
- W2924562010 cites W1984328540 @default.
- W2924562010 cites W1987108013 @default.
- W2924562010 cites W1988456139 @default.
- W2924562010 cites W1997406551 @default.
- W2924562010 cites W2002434904 @default.
- W2924562010 cites W2004009051 @default.
- W2924562010 cites W2008892442 @default.
- W2924562010 cites W2016856544 @default.
- W2924562010 cites W2032683573 @default.
- W2924562010 cites W2038766003 @default.
- W2924562010 cites W2040320667 @default.
- W2924562010 cites W2042544749 @default.
- W2924562010 cites W2052983658 @default.
- W2924562010 cites W2054112305 @default.
- W2924562010 cites W2063295519 @default.
- W2924562010 cites W2073331228 @default.
- W2924562010 cites W2075629948 @default.
- W2924562010 cites W2094859818 @default.
- W2924562010 cites W2096786319 @default.
- W2924562010 cites W2103300954 @default.
- W2924562010 cites W2104358275 @default.
- W2924562010 cites W2118935287 @default.
- W2924562010 cites W2122071290 @default.
- W2924562010 cites W2125060052 @default.
- W2924562010 cites W2128094021 @default.
- W2924562010 cites W2128473487 @default.
- W2924562010 cites W2135919238 @default.
- W2924562010 cites W2148158834 @default.
- W2924562010 cites W2157265784 @default.
- W2924562010 cites W2160416386 @default.
- W2924562010 cites W2160813072 @default.
- W2924562010 cites W2167399895 @default.
- W2924562010 cites W2172253460 @default.
- W2924562010 cites W2313950434 @default.
- W2924562010 cites W2377750233 @default.
- W2924562010 cites W2417540039 @default.
- W2924562010 cites W2523580403 @default.
- W2924562010 cites W2546974093 @default.
- W2924562010 cites W2563038139 @default.
- W2924562010 cites W2736410190 @default.
- W2924562010 cites W2751318493 @default.
- W2924562010 cites W2763335706 @default.
- W2924562010 cites W2767277262 @default.
- W2924562010 cites W2792358988 @default.
- W2924562010 cites W2792795666 @default.
- W2924562010 cites W2796525679 @default.
- W2924562010 cites W2799321885 @default.
- W2924562010 cites W4255308885 @default.
- W2924562010 cites W2149819554 @default.
- W2924562010 cites W2280093144 @default.
- W2924562010 doi "https://doi.org/10.3389/fphys.2019.00327" @default.
- W2924562010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6445135" @default.
- W2924562010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30971955" @default.
- W2924562010 hasPublicationYear "2019" @default.
- W2924562010 type Work @default.
- W2924562010 sameAs 2924562010 @default.
- W2924562010 citedByCount "16" @default.
- W2924562010 countsByYear W29245620102021 @default.
- W2924562010 countsByYear W29245620102022 @default.
- W2924562010 countsByYear W29245620102023 @default.
- W2924562010 crossrefType "journal-article" @default.
- W2924562010 hasAuthorship W2924562010A5034704040 @default.
- W2924562010 hasAuthorship W2924562010A5035556877 @default.
- W2924562010 hasAuthorship W2924562010A5042133263 @default.
- W2924562010 hasAuthorship W2924562010A5042851658 @default.
- W2924562010 hasAuthorship W2924562010A5045804141 @default.
- W2924562010 hasAuthorship W2924562010A5048902087 @default.
- W2924562010 hasAuthorship W2924562010A5058865296 @default.
- W2924562010 hasAuthorship W2924562010A5077508602 @default.
- W2924562010 hasAuthorship W2924562010A5081444992 @default.
- W2924562010 hasAuthorship W2924562010A5086070985 @default.
- W2924562010 hasBestOaLocation W29245620101 @default.
- W2924562010 hasConcept C126322002 @default.
- W2924562010 hasConcept C203014093 @default.
- W2924562010 hasConcept C203565725 @default.
- W2924562010 hasConcept C2776151105 @default.
- W2924562010 hasConcept C2776694085 @default.